Clinical trial NCT06944457: Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
Official title: A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Cancer
Solid Tumor Cancer
Biomarkers
Keywords: PTEN Loss
KRAS mutation
Lead sponsor: Pharosgen Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2025-04-25
Enrollment: 24
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: conventional 3+3 design with 4 arms (cohorts) to find RP2D.
Primary purpose: TREATMENT

Brief summary: A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor


Eligibility criteria: Inclusion Criteria:

1. 19 to 75 years of age
2. A histologically or cytologically confirmed, metastatic or unresectable advanced solid tumor patient who has used all available existing standard therapy but tumor progression is confirmed and further treatment tool is absent, or patient showing resistant or inadequate to standard therapy.
3. KRAS mutation or PTEN loss is confirmed in tumor tissues prior to screening, and there is a documented record of this
4. Patients without the history of administration of anthracycline drugs and/or anthracene
5. Patients with at least one measurable or unmeasurable but assessable lesion in accordance with Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.1
6. In screening and C1D1, subjects with appropriate hematologic, kidney, and liver function confirmed by the following laboratory test (one more laboratory test is permitted during the screening period)

<!-- -->

1. white blood cell (WBC) ≥ 3,500/mm3
2. absolute neutrophil count (ANC) ≥ 1,500/mm3 (without CSF administration within 2 weeks prior to C1D1)
3. platelets ≥ 100,000/mm3 (without transfusion within 2 weeks prior to C1D1)
4. hemoglobin (Hb) ≥ 10 g/dL (without transfusion within 2 weeks prior to C1D1)
5. total bilirubin ≤ 1.5 times the normal upper limit (However, in case of Gilbert syndrome, this patient can participate in this clinical trial regardless of the results of total bilirubin
6. aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the normal upper limit (five times of the normal upper limit in case of liver metastasis)
7. albumin ≥ 2.5 g/dL
8. serum creatinine ≤ 1.5 times the normal upper limit
9. INR ≤ 1.5 times the normal upper limit 7) Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 8) Patients with an expected survival period of more than 12 weeks 9) Patients who have recovered from previous therapy-related adverse event to Common Terminology Criterion for Adverse Events (CTCAE) version 5.0 grade 1 or below or to C1D1 levels (However, sHair loss (regardless of grade), subjects can be enrolled if they have with hair loss (regardless of grade) or peripheral neuropathy below grade 2 or laboratory test results show that they do not meet the exclusion criteria) can be enrolled.) 10) Patients, who after understanding all the relevant information of this clinical trial, decides to participate, and voluntarily signed a written agreement.

Exclusion Criteria:

1. Within 4 weeks prior to the C1D1, subjects who underwent surgery, chemotherapy (cytotoxic, targeted antitumor drugs), immunotherapy, biological or hormonal therapy, or radiation therapy at areas exceeding 30% of bone marrow for the treatment of this clinical trial's target disease
2. Participation in other interventional clinical trials (administration of investigational new drugs or use of investigational medical devices) within 4 weeks prior to C1D1
3. Subjects who are identified with the following comorbidities during screening

   - Clinically significant symptomatic or uncontrolled central nervous system metastasis (but can participate in this clinical trial if systemic corticosteroids have not been administered for more than 2 weeks prior to C1D1 and the condition is stable)
   * Heart disease that could affect this clinical trial (left ventricular ejection fraction (LVEF) \<50%, congestive heart failure with New York Heart Association (NYHA) class II or higher, history of myocarditis, myocardial infarction or unstable angina within 24 weeks before C1D1, uncontrolled cardiac dysrhythmia by appropriate medication, coronary artery disease, etc.)
   * History of thrombosis (e.g., thrombophlebitis, etc.)
   * Uncontrolled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg)
   * Clinically significant ascites
   * Subjects who are infected with or carrying hepatitis B virus (HBV) or hepatitis C virus (HCV)\* \* When screening, serology tests show that any one of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis B core antibody-immunoglobulin M (HBcAb-IgM), and hepatitis C virus antibody (HCV Ab) (However, if the HCV Ab test result is suspected to be false positive or positive due to past infection, HCV RNA test may be performed at each institution under the judgement of investigator and the HCV Ab and RNA test results are integrated to decide whether HCV is infected.)
4. The following medical history is identified during screening

   * Chickenpox or varicella zoster infection within 12 weeks prior to C1D1
   * Uncontrolled active infectious diseases including known human immunodeficiency virus (HIV) positives
5. Subjects with a history of administration of the following drugs during screening or C1D1

   * Vaccination against yellow fever within 4 weeks prior to C1D1
   * Penitoin within 1 week prior to C1D1
   * G-CSF administration to correct absolute neutrophil count (ANC) levels within 2 weeks prior to C1D1

     -- Transfusion of packed red cells or platelets to correct platelets or hemoglobin levels within 2 weeks prior to C1D1
   * Trastuzumab within 28 weeks prior to C1D1
6. Pregnant women, nursing mothers, and fertile women with plan for pregnancy
7. Fertile women or men who do not agree to abstain from sex or perform effective contraception methods for at least 24 weeks after the end of administration\* \[\* Effective Contraception\]

   * Hormone contraception (oral contraceptives, subcutaneous implants, etc.)

     * Intrauterine device (IUD) or implantation of an intrauterine system (IUS) ③ Infertility procedures or surgeries (vasectomy, bilateral oviduct ligation/excision, hysterectomy, etc.)

       * Double contraception (concurrent use of contraceptive methods from ①\~③ and condoms for men or women) ⑤ Absolute abstinence: Based on investigator's judgment, thorough abstinence from sex is approved if the subject's age, occupation, lifestyle, or sexual orientation guarantee contraception. However, periodic abstinence (menstrual cycle, mucus method, symptomatic body temperature method, etc.), resection, and withdrawal method (coitus interruptus) are not recognized as appropriate contraception methods.
8. Subjects who have a history of allergies to doxorubicin or the excipient of MPD-1 or is suspicious of allergy
9. Subjects in a state of prohibiting, limiting, or disrupting the assessments specified in the clinical trial (e.g., a history of alcohol or drug abuse within two years prior to C1D1)
10. Subjects considered as unsuitable for participation in the clinical trial by the investigator (e.g., if the patient's health is unsuitable or participation in this clinical trial is not the best treatment for the patient)

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Determination
timeFrame: From first treatment to the end of treatment at 18 weeks
measure: Incidence of Treatment-Related Adverse Events
timeFrame: From first treatment to the end of treatment at 18 weeks
measure: Electrocardiogram (ECG) QT Interval Prolongation
timeFrame: From first treatment to the end of treatment at 18 weeks
Secondary outcomes:
measure: Pharmacokinetic Outcome Measures
timeFrame: From first treatment (Cycle 1, Day 1) to one week after the first treatment (Cycle 1, Day 8)
measure: Pharmacokinetic Outcome Measures
timeFrame: From first treatment (Cycle 1, Day 1) to one week after the first treatment (Cycle 1, Day 8)
measure: Pharmacokinetic Outcome Measures
timeFrame: From first treatment (Cycle 1, Day 1) to one week after the first treatment (Cycle 1, Day 8)
measure: Pharmacokinetic Outcome Measures
timeFrame: From first treatment (Cycle 1, Day 1) to one week after the first treatment (Cycle 1, Day 8)
measure: Pharmacokinetic Outcome Measures
timeFrame: From first treatment (Cycle 1, Day 1) to one week after the first treatment (Cycle 1, Day 8)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Pharosgen Co.,Ltd
name: Sangyoon Kim, MD, PhD
role: STUDY_DIRECTOR
References: